REG - Hutchmed China Ltd - Exercise of Share Options by a Director

HUTCHMED (China)Announcement

07/08/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230807:nRSG4948Ia&default-theme=true

RNS Number : 4948I  Hutchmed (China) Limited  07 August 2023

Exercise of Share Options by a Director

 

 

Hong Kong, Shanghai & Florham Park, NJ - Monday, August 7, 2023: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the "Company")
(Nasdaq/AIM: HCM, HKEX: 13) today announces that it has issued a total of
3,000,000 ordinary shares of US$0.10 each ("Ordinary Shares") following the
exercise of share options by Dr Weiguo Su, Executive Director, Chief Executive
Officer and Chief Scientific Officer, at an exercise price of GBP1.97 per
Ordinary Share on August 7, 2023 (the "Exercise of Options").

 

Following the Exercise of Options, Dr Su is beneficially interested in
5,000,000 Ordinary Shares (Note 1) and 632,505 American Depositary Shares
("ADSs") (Note 2), representing 0.94% of the current issued share capital of
the Company.

 

Notes:

1.         5,000,000 Ordinary Shares included (i) 3,000,000 Ordinary
Shares currently held by Dr Su, and (ii) share options for 2,000,000 Ordinary
Shares granted under Share Option Scheme

2.         632,505 ADSs included (i) 143,518 ADSs currently held by Dr
Su, (ii) share options for 395,442 ADSs granted under Share Option Scheme and
(iii) 93,545 ADSs as beneficiary of a trust under long term incentive plan.

 

The notification set out below is provided in accordance with the requirements
of the EU Market Abuse Regulation.

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Dr Weiguo Su

 2    Reason for the notification

 a)   Position/status                                               Executive Director, Chief Executive Officer and Chief Scientific Officer

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   Ordinary Shares of US$0.10 each

      Identification code

                                                                    DI ISIN: KYG4672N1198

 b)   Nature of the transaction                                     Exercise of share options for 3,000,000 Ordinary Shares on August 7, 2023 at

                                                             exercise price of GBP1.97 per Ordinary Share

 c)   Price(s) and volume(s)
                                                                                          Price(s)              Volume(s)
                                                                                          GBP1.97               3,000,000

 d)   Aggregated information                                        Aggregated volume: 3,000,000 Ordinary Shares

                                                             Price information: GBP5,910,000
      - Aggregated volume
      - Price

 e)   Date of the transaction                                       2023-08-07

 f)   Place of the transaction                                      Outside a trading venue

 

Aggregated volume: 3,000,000 Ordinary Shares

Price information: GBP5,910,000

 

e)

 

Date of the transaction

 

2023-08-07

 

 

f)

 

Place of the transaction

 

Outside a trading venue

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Forward-Looking Statements

 

This announcement contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements involve risks and uncertainties.
Existing and prospective investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof.
For further discussion of these and other risks, see HUTCHMED's filings with
the U.S. Securities and Exchange Commission, on AIM and on HKEX. HUTCHMED
undertakes no obligation to update or revise the information contained in this
announcement, whether as a result of new information, future events or
circumstances or otherwise.

 

CONTACTS
 Investor Enquiries
 Mark Lee, Senior Vice President                                   +852 2121 8200
 Annie Cheng, Vice President                                       +1 (973) 306 4490

 Media Enquiries
 Americas - Brad Miles,                                            +1 (917) 570 7340 (Mobile) / bmiles@s (mailto:bmiles@soleburystrat.com)

Solebury Strategic Communications                                oleburystrat (mailto:bmiles@soleburystrat.com) .com
                                                                   (mailto:bmiles@soleburystrat.com)
 Europe - Ben Atwell / Alex Shaw,                                  +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

FTI Consulting                                                   +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                                   (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi, Brunswick                                         +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                                   (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon   +44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGZGGRNNNGFZG